Jeremey Schreiber, MSN, PMHNP-BC

July 26, 2023

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, provide their practice pearls for community psychiatrists and psychiatric nurse practitioners who care for patients with major depressive disorder (MDD) to optimize their treatment and management.

July 26, 2023

Experts provide an overview of novel treatments, including glutamatergic, GABAergic, and psychedelic drugs, that are either approved or currently being evaluated in clinical studies for MDD (major depressive disorders).

July 19, 2023

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss the typical strategies for switching therapies for major depressive disorder (MDD).

July 19, 2023

Practitioners discuss the need to treat patients with major depressive disorder (MDD) to a complete remission vs a decline in symptomology.

July 12, 2023

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss best practices for monitoring and follow-up with patients with major depressive disorder (MDD) to ensure treatment efficacy and safety.

July 12, 2023

Practitioners discuss their approach to treatment with their patients with major depressive disorder (MDD).

July 05, 2023

Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.

July 05, 2023

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).

June 30, 2023

Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).

June 30, 2023

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, comment on the perception of major depressive disorder (MDD) within the healthcare community and the clinical and practical implications of is this condition.